Pomalidomide vs Lenalidomide — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Thalidomide Analog

Pomalidomide

Brand: Pomalyst

First FDA approval: 2013-02-18

Thalidomide Analog

Lenalidomide

Brand: Revlimid

First FDA approval: 2005-12-27

Lowest NADACAcquisition cost floor across all NDCs

—Per unit

Average NADACAcross all dosage forms and strengths

—

Generic manufacturersActive ANDA holders — FDA Orange Book

520 total ANDAs filed

18110 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$3.29BFull year

$10.15BFull year

Part D claims (CY24)Total fills, all strengths

149K26K beneficiaries

666K125K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$22,085Per claim, all NDCs

$15,236Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

1308Substantial friction

2046Substantial friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes5 manufacturers

Yes18 manufacturers